By Daniella Parra
ProSomnus, Inc. (NASDAQ: OSA) announced the presentation of three abstracts at the 2023 SLEEP Annual Meeting, demonstrating the effectiveness and safety of their Precision Oral Appliance Therapy (OAT) devices for treating Obstructive Sleep Apnea (OSA), the company said.
“The collective research demonstrates that ProSomnus’s Precision Oral Appliance Therapy (OAT) devices are associated with significantly fewer adverse event reports than other OATs, CPAP and hypoglossal nerve stimulation treatments,” stated John E. Remmers, MD, Chief Scientist of ProSomnus. “Furthermore, the data show that Precision OAT can efficaciously treat all severities of OSA, making a strong case for the widespread adoption of this less invasive, patient-preferred treatment modality.”
Contact:
Editor@Executives-edge.com
